Freire Javier, García-Berbel Pilar, Caramelo Belén, García-Berbel Lucía, Ovejero Victor J, Cadenas Nuria, Azueta Ainara, Gómez-Román Javier
Pathology Department, University Hospital Marques de Valdecilla, Avda. Marqués de Valdecilla s/n, 39008 Santander, Spain.
Pathology and Molecular Pathology Unit, IDIVAL, Avenida Cardenal Herrera Oria s/n, 39011 Santander, Spain.
Biomedicines. 2023 Sep 8;11(9):2496. doi: 10.3390/biomedicines11092496.
Determining the infiltration of carcinomas is essential for the proper follow-up and treatment of cancer patients. However, it continues to be a diagnostic challenge for pathologists in multiple types of tumors. In previous studies (carried out in surgical specimens), the protein COL11A1 has been postulated as an infiltration marker mainly expressed in the extracellular matrix (ECM). We hypothesized that a differential expression of COL11A1 may exist in the peritumoral stroma of tumors that have acquired infiltrating properties and that it may be detected in the small biopsies usually available in normal clinical practice.
In our study, we performed immunohistochemical staining in more than 350 invasive and noninvasive small samples obtained via core needle biopsy (CNB), colonoscopy, or transurethral resection of bladder tumor (TURBT) of breast, colorectal, bladder, and ovarian cancer.
Our results revealed that COL11A1 immunostaining had a sensitivity to classify the samples into infiltrative vs. noninfiltrative tumors of 94% (breast), 97% (colorectal), >90% (bladder), and 74% (ovarian); and a specificity of 97% (breast), 100% (colorectal), and >90% (bladder). In ovarian cancer, the negative predictive value (0.59) did not present improvement over the usual histopathological markers. In all samples tested, the cumulative sensitivity was 86% and the specificity 96% ( < 0.0001).
COL11A1-positive immunostaining in small biopsies of breast, colon, bladder and ovarian cancer is an accurate predictive marker of tumor infiltration that can be easily implemented in daily clinical practice.
确定癌组织浸润情况对于癌症患者的恰当随访和治疗至关重要。然而，对于多种类型的肿瘤，这仍然是病理学家面临的诊断挑战。在先前的研究（在手术标本中进行）中，蛋白质COL11A1被假定为一种主要在细胞外基质（ECM）中表达的浸润标志物。我们推测，在具有浸润特性的肿瘤瘤周基质中可能存在COL11A1的差异表达，并且在正常临床实践中通常可用的小活检标本中可能检测到这种差异表达。
在我们的研究中，我们对通过粗针活检（CNB）、结肠镜检查或经尿道膀胱肿瘤切除术（TURBT）获取的350多个乳腺、结直肠、膀胱和卵巢癌的侵袭性和非侵袭性小样本进行了免疫组织化学染色。
我们的结果显示，COL11A1免疫染色将样本分类为浸润性肿瘤与非浸润性肿瘤的敏感性分别为94%（乳腺）、97%（结直肠）、>90%（膀胱）和74%（卵巢）；特异性分别为97%（乳腺）、100%（结直肠）和>90%（膀胱）。在卵巢癌中，阴性预测值（0.59）与常用的组织病理学标志物相比并无改善。在所有测试样本中，累积敏感性为86%，特异性为96%（<0.0001）。
乳腺、结肠、膀胱和卵巢癌小活检标本中COL11A1阳性免疫染色是肿瘤浸润的准确预测标志物，可在日常临床实践中轻松应用。
